Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molybdenum Cofactor Catabolism Unravels the Physiological Role of the Drug Metabolizing Enzyme Thiopurine S-Methyltransferase.

Clinical pharmacology and therapeutics - 1 Oct 2022

Pristup Julika, Schaeffeler Elke, Arjune Sita, Hofmann Ute, Angel Santamaria-Araujo Jose, Leuthold Patrick, Friedrich Nele, Nauck Matthias, Mayr Simon, Haag Mathias, Muerdter Thomas, Marner Franz-Josef, Relling Mary V, Evans William E, Schwarz Guenter, Schwab Matthias

Abstract excerpt

Therapy of molybdenum cofactor (Moco) deficiency has received US Food and Drug Administration (FDA) approval in 2021. Whereas urothione, the urinary excreted catabolite of Moco, is used as diagnostic biomarker for Moco-deficiency, its catabolic pathway remains unknown. Here, we identified the urothione-synthesizing methyltransferase using mouse liver tissue by anion exchange/size exclusion chromatography and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genotype
Share to Methyltransferases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mice, Knockout

Share to Molybdenum Cofactors

Source

Open in PubMed Open full text

Identifiers

PMID: 35538648
DOI: 10.1002/cpt.2637
PMCID: PMC9474665

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molybdenum Cofactor Catabolism Unravels the Physiological Role of the Drug Metabolizing Enzyme Thiopurine S-Methyltransferase.PMID 35538648Read ↗

Implications of tioguanine dosing in IBD patients with a TPMT deficiencySemantic proximity Read ↗

Thiopurine S-Methyltransferase as a Pharmacogenetic Biomarker: Significance of Testing and Review of Major Methods.Semantic proximity Read ↗

Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?Semantic proximity Read ↗

Studies in alkaptonuria reveal new roles beyond drug clearance for phase I and II biotransformations in tyrosine metabolismSemantic proximity Read ↗

Personalization of thiopurine therapy: Current recommendations and future perspectives.Semantic proximity Read ↗

Usefulness of thiopurine methyltransferase and thiopurine metabolite analysis in clinical practice in patients with inflammatory bowel diseases.Semantic proximity Read ↗

Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond.Semantic proximity Read ↗

Interindividual variability in TPMT enzyme activity: 10 years of experience with thiopurine pharmacogenetics and therapeutic drug monitoring.Semantic proximity Read ↗

Mouse model for molybdenum cofactor deficiency type B recapitulates the phenotype observed in molybdenum cofactor deficient patients.Semantic proximity Read ↗

Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directionsSemantic proximity Read ↗

Very important pharmacogene summary: thiopurine S-methyltransferase.Semantic proximity Read ↗

Hereditary Tyrosinemia Type 1 Mice under Continuous Nitisinone Treatment Display Remnants of an Uncorrected Liver Disease Phenotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.